janssen science wordmark
Oncology
Oncology

Amivantamab Plus Chemotherapy vs Chemotherapy in EGFR-mutated, Advanced Non-small Cell Lung Cancer After Disease Progression on Osimertinib: 2nd Interim Overall Survival From MARIPOSA-2